Literature DB >> 28375559

Transfusion of 35-day-stored red blood cells does not alter lipopolysaccharide tolerance during human endotoxemia.

Anna L Peters1,2, Maike E van Hezel1,2,3, Robert B Klanderman1,2, Anita M Tuip-de Boer1,2, W Joost Wiersinga4, Anne H van der Spek5, Robin van Bruggen3, Dirk de Korte3,6, Nicole P Juffermans1,2, Alexander P J Vlaar1,2.   

Abstract

BACKGROUND: Transfusion-related immunomodulation (TRIM) encompasses immunosuppressive and proinflammatory effects induced by red blood cell (RBC) transfusion. Changes that occur during storage in the RBC product have been hypothesized to underlie TRIM, mediated by tolerance of toll-like receptors (TLR). We investigated whether transfusion of 35-day-stored autologous RBCs alters cytokine production in response to stimulation with lipopolysaccharide (LPS) or lipotheic acid (LTA), in a clinically relevant model of endotoxemia. STUDY DESIGN AND METHODS: Eighteen volunteers received 2 ng/kg LPS intravenously, followed by normal saline or 2- or 35-day-stored autologous RBC transfusion. Before LPS, before transfusion, and 6 hours after transfusion blood was collected to measure cytokine gene expression. Whole blood was used for ex vivo stimulation with LPS and LTA, after which cytokine levels were measured with enzyme-linked immunosorbent assay.
RESULTS: In vivo LPS induced a biphasic response in cytokine mRNA with peak values 2 hours after LPS infusion. Storage time of RBC transfusion did not influence cytokine mRNA levels. In vivo infusion of LPS resulted in tolerance for ex vivo stimulation with LPS and LTA. However, transfusion of either fresh or stored RBCs did not further affect the capacity to produce cytokines after ex vivo stimulation.
CONCLUSION: In a clinically relevant model of human endotoxemia, autologous transfusion of 35-day-stored RBCs does not influence cytokine mRNA levels nor does it change the capacity of white blood cells in whole blood to produce cytokines after ex vivo stimulation with LPS or LTA.
© 2017 The Authors Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28375559     DOI: 10.1111/trf.14087

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

Review 1.  Transfusion-related immunomodulation: a reappraisal.

Authors:  Lyla A Youssef; Steven L Spitalnik
Journal:  Curr Opin Hematol       Date:  2017-11       Impact factor: 3.284

2.  A comparison of different methods of red blood cell leukoreduction and additive solutions on the accumulation of neutrophil-priming activity during storage.

Authors:  Michele M Loi; Marguerite Kelher; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; F Bernadette West; Crystal Stanley; Matthew Briel; Christopher C Silliman
Journal:  Transfusion       Date:  2018-09-01       Impact factor: 3.157

3.  Transfusion-related Acute Lung Injury: 36 Years of Progress (1985-2021).

Authors:  Pearl Toy; Mark R Looney; Mark Popovsky; Miodrag Palfi; Gösta Berlin; Catherine E Chapman; Paula Bolton-Maggs; Michael A Matthay
Journal:  Ann Am Thorac Soc       Date:  2022-05

4.  Y-RNA subtype ratios in plasma extracellular vesicles are cell type- specific and are candidate biomarkers for inflammatory diseases.

Authors:  Tom A P Driedonks; Sanne Mol; Sanne de Bruin; Anna-Linda Peters; Xiaogang Zhang; Marthe F S Lindenbergh; Boukje M Beuger; Anne-Marieke D van Stalborch; Thom Spaan; Esther C de Jong; Erhard van der Vries; Coert Margadant; Robin van Bruggen; Alexander P J Vlaar; Tom Groot Kormelink; Esther N M Nolte-'t Hoen
Journal:  J Extracell Vesicles       Date:  2020-05-26

5.  Red blood cell transfusion results in adhesion of neutrophils in human endotoxemia and in critically ill patients with sepsis.

Authors:  Maike E van Hezel; Margit Boshuizen; Anna L Peters; M Straat; Alexander P Vlaar; Angelique M E Spoelstra-de Man; Michael W T Tanck; Anton T J Tool; Boukje M Beuger; Taco W Kuijpers; Nicole P Juffermans; Robin van Bruggen
Journal:  Transfusion       Date:  2019-12-05       Impact factor: 3.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.